Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone. Eli Lilly & Co’s
Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.
Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.
Follow us on:
Easily access major global news with a strong focus on Africa. As well as the main stories of the day, we like to accentuate positive stories about Africa across all genres including Politics, Business, Commerce, Science, Sports, Arts & Culture, Showbiz and Fashion.
We broadcast 24 hours a day from our studios in London and New York and can be seen here in the UK and across Europe on the Sky platform (Sky channel 516), Freeview (Channel 136) as well as in the USA on the Centric channel and also on the Hot bird platform, which transmits to Europe, North Africa and the Middle East.
© 2023 Arise News - Part of the Arise Media Group.
